» Articles » PMID: 21385934

Targeting Galectin-1 in Carcinoma-associated Fibroblasts Inhibits Oral Squamous Cell Carcinoma Metastasis by Downregulating MCP-1/CCL2 Expression

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2011 Mar 10
PMID 21385934
Citations 71
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Carcinoma-associated fibroblasts (CAFs) in tumor stroma play an important role in tumor progression and have been associated with a poor prognosis in oral squamous cell carcinoma (OSCC). However, how CAFs influence OSCC malignancy and whether normalizing CAFs inhibits cancer progression remain unclear.

Experimental Design: The relationship between the expression of Galectin-1 (Gal-1) and alpha-smooth muscle actin (α-SMA, a CAF marker) in OSCC patient samples and primary cultured CAFs was examined by quantitative real-time PCR, Western blotting, and immunofluorescence. To examine the effect of Gal-1 on CAF activation and CAF-mediated tumor invasion and migration in vitro, Gal-1 expression was knocked down by small hairpin RNA. Finally, cancer cells and CAFs were coimplanted into SCID mice to evaluate the effect of Gal-1 on CAF-modulated tumor progression in vivo.

Results: Gal-1 expression is positively associated with α-SMA in the stroma of OSCC specimens. Gal-1 knockdown decreases activated CAF characteristics, resulting in a decrease in α-SMA expression and extracellular matrix protein production. Notably, blocking Gal-1 expression significantly inhibits CAF-conditioned medium-induced tumor cell migration and invasion, possibly by reducing the production of monocyte chemotactic protein-1 (MCP-1/CCL2). MCP-1 induces the migration of OSCC cells by binding to the receptor CCR2; adding an MCP-1 antibody to CAF-conditioned medium that inhibits the interaction between MCP-1 and CCR2 abolishes migration. Finally, we found that Gal-1 knockdown in CAFs significantly reduces CAF-augmented tumor growth and metastasis in vivo.

Conclusions: Our findings demonstrate that Gal-1 regulates CAF activation and indicate that targeting Gal-1 in CAFs inhibits OSCC metastasis by modulating MCP-1 expression.

Citing Articles

Therapeutic Targeting of the Galectin-1/miR-22-3p Axis Regulates Cell Cycle and EMT Depending on the Molecular Subtype of Breast Cancer.

Kim J, Lee J, Jung E, Son Y, Park H, Kim J Cells. 2025; 14(4).

PMID: 39996781 PMC: 11854374. DOI: 10.3390/cells14040310.


The Microenvironment in DCIS and Its Role in Disease Progression.

Roozitalab M, Prekete N, Allen M, Grose R, Jones J Adv Exp Med Biol. 2025; 1464():211-235.

PMID: 39821028 DOI: 10.1007/978-3-031-70875-6_12.


Cancer-associated fibroblasts as therapeutic targets for cancer: advances, challenges, and future prospects.

Cao Z, Quazi S, Arora S, Osellame L, Burvenich I, Janes P J Biomed Sci. 2025; 32(1):7.

PMID: 39780187 PMC: 11715488. DOI: 10.1186/s12929-024-01099-2.


Galectin-1 Promotes Gastric Carcinoma Progression and Cisplatin Resistance Through the NRP-1/c-JUN/Wee1 Pathway.

Pan Z, Xu G, Zhang Y, Wu M, Yu J, He X J Gastric Cancer. 2024; 24(3):300-315.

PMID: 38960889 PMC: 11224716. DOI: 10.5230/jgc.2024.24.e25.


Single-cell analysis defines LGALS1+ fibroblasts that promote proliferation and migration of intrahepatic cholangiocarcinoma.

Cao Q, Yang J, Jiang L, Yang Z, Fan Z, Chen S J Mol Cell Biol. 2024; 16(6).

PMID: 38862197 PMC: 11639627. DOI: 10.1093/jmcb/mjae023.